과제정보
The authors thank the nurses and technicians at Seoul St. Mary's Hospital for their work supporting safe and accurate data collection in this study. Special note of gratitude to Ms. Myoung Hee Lee for caring for the patients throughout the study.
참고문헌
- Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85
- Hyvakka A, Virtanen V, Kemppainen J, Gronroos TJ, Minn H, Sundvall M. More than meets the eye: scientific rationale behind molecular imaging and therapeutic targeting of prostate-specific membrane antigen (PSMA) in metastatic prostate cancer and beyond. Cancers (Basel) 2021;13:2244
- Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol 2016;13:226-235 https://doi.org/10.1038/nrurol.2016.26
- Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:1976-1983 https://doi.org/10.1007/s00259-015-3125-3
- Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 2019;60:517-523 https://doi.org/10.2967/jnumed.118.219352
- Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385:1091-1103 https://doi.org/10.1056/NEJMoa2107322
- Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397:797-804 https://doi.org/10.1016/S0140-6736(21)00237-3
- Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMAALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging 2021;48:893-903 https://doi.org/10.1007/s00259-020-05022-3
- Benesova M, Umbricht CA, Schibli R, Muller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm 2018;15:934-946 https://doi.org/10.1021/acs.molpharmaceut.7b00877
- Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. Firstin-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019;46:148-158 https://doi.org/10.1007/s00259-018-4096-y
- Kelly J, Amor-Coarasa A, Ponnala S, Nikolopoulou A, Williams C Jr, Schlyer D, et al. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. Eur J Nucl Med Mol Imaging 2018;45:1841-1851 https://doi.org/10.1007/s00259-018-4004-5
- Vaughn BA, Loveless CS, Cingoranelli SJ, Schlyer D, Lapi SE, Boros E. Evaluation of 177Lu and 47Sc picaga-linked, prostate-specific membrane antigen-targeting constructs for their radiotherapeutic efficacy and dosimetry. Mol Pharm 2021;18:4511-4519 https://doi.org/10.1021/acs.molpharmaceut.1c00711
- Ling X, Latoche JD, Choy CJ, Kurland BF, Laymon CM, Wu Y, et al. Preclinical dosimetry, imaging, and targeted radionuclide therapy studies of Lu-177-labeled albumin-binding, PSMA-targeted CTT1403. Mol Imaging Biol 2020;22:274-284 https://doi.org/10.1007/s11307-019-01404-8
- Lee BS, Kim MH, Chu SY, Jung WJ, Jeong HJ, Lee K, et al. Improving theranostic gallium-68/lutetium-177-labeled PSMA inhibitors with an albumin binder for prostate cancer. Mol Cancer Ther 2021;20:2410-2419 https://doi.org/10.1158/1535-7163.MCT-21-0251
- Shin D, Ha S, O JH, Rhew SA, Yoon CE, Kwon HJ, et al. A single dose of novel PSMA-targeting radiopharmaceutical agent [177Lu]Ludotadipep for patients with metastatic castration-resistant prostate cancer: phase I clinical trial. Cancers (Basel) 2022;14:6225
- Lee I, Lim I, Byun BH, Kim BI, Choi CW, Woo SK, et al. A microdose clinical trial to evaluate [18F]florastamin as a positron emission tomography imaging agent in patients with prostate cancer. Eur J Nucl Med Mol Imaging 2021;48:95-102 https://doi.org/10.1007/s00259-020-04883-y
- Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies. Eur Urol 2018;73:485-487 https://doi.org/10.1016/j.eururo.2017.10.027
- Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 2018;78:4786-4789 https://doi.org/10.1158/0008-5472.CAN-18-0125
- Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S
- Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjogreen-Gleisner K, et al. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med 2016;57:151-162 https://doi.org/10.2967/jnumed.115.159012
- Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36:1138-1146 https://doi.org/10.1007/s00259-009-1072-6
- Sjogreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor-and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging 2022;49:1778-1809 https://doi.org/10.1007/s00259-022-05727-7
- Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, et al. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther 2017;26:62-68 https://doi.org/10.4274/mirt.08760
- Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, et al. Tumor sink effect in 68Ga-PSMA-11 PET: myth or reality? J Nucl Med 2022;63:226-232 https://doi.org/10.2967/jnumed.121.261906
- Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-1475
- Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847-1856 https://doi.org/10.1007/s00259-008-0778-1
- Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:42-51 https://doi.org/10.1007/s00259-015-3174-7
- Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med 2020;61:857-865 https://doi.org/10.2967/jnumed.119.236414
- Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, et al. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med 2005;46:634-641
- Uribe C, Peterson A, Van B, Fedrigo R, Carlson J, Sunderland J, et al. An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI dosimetry challenge. J Nucl Med 2021;62(Suppl 3):36S-47S https://doi.org/10.2967/jnumed.121.262748
- Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using 177Lu-DKFZPSMA-617. Nucl Med Mol Imaging 2021;55:237-244 https://doi.org/10.1007/s13139-021-00713-7
- Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges. Nucl Med Mol Imaging 2017;51:202-211 https://doi.org/10.1007/s13139-016-0439-4
- Jacobson O, Kiesewetter DO, Chen X. Albumin-binding Evans blue derivatives for diagnostic imaging and production of long-acting therapeutics. Bioconjug Chem 2016;27:2239-2247 https://doi.org/10.1021/acs.bioconjchem.6b00487
- Umbricht CA, Benesova M, Schibli R, Muller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm 2018;15:2297-2306 https://doi.org/10.1021/acs.molpharmaceut.8b00152
- Kuo HT, Lin KS, Zhang Z, Uribe CF, Merkens H, Zhang C, et al. 177Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio. J Nucl Med 2021;62:521-527 https://doi.org/10.2967/jnumed.120.250738
- Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, et al. 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. J Nucl Med 2020;61:1772-1778 https://doi.org/10.2967/jnumed.120.242263
- Wahl RL, Sgouros G, Iravani A, Jacene H, Pryma D, Saboury B, et al. Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns. J Nucl Med 2021;62(Suppl 3):23S-35S https://doi.org/10.2967/jnumed.121.262751
- Hindorf C, Linden O, Tennvall J, Wingardh K, Strand SE. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy. Acta Oncol 2005;44:579-588 https://doi.org/10.1080/02841860500244294